NPCE(NPCE)
NPCE
ANALYST COVERAGE10 analysts
BUY
▲ +36.7%upside to target
L $20.00
Med $21.00consensus
H $22.00PRICE
Prev Close
15.79
Open
15.49
Day Range15.01 – 15.68
15.01
15.68
52W Range7.56 – 19.60
7.56
19.60
65% of range
VOLUME & SIZE
Avg Volume
210.6K
FUNDAMENTALS
P/E Ratio
-23.6x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
0.65
Low vol
TECHNICAL
RSI (14)
53
Bullish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 19
DEx-Dividend
In 88 days
Aug 14
PDividend Pay
In 105 days
Aug 31
Key MetricsTTM
Market Cap$523.68M
Revenue TTM$99.53M
Net Income TTM-$21.57M
Free Cash Flow-$9.84M
Gross Margin78.3%
Operating Margin-16.8%
Net Margin-21.7%
Return on Equity-120.7%
Return on Assets-21.8%
Debt / Equity4.87
Current Ratio5.38
EPS TTM$-0.64
NPCE News
About
Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients suffering from drug-resistant epilepsy, and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
Martha J. MorrellChief Medical Officer
Patrick F. WilliamsChief Financial Officer
Scott R. SchaperHead of Investor Relations
Chris ReeseSenior Vice President of Sales
Dylan JohnChief of Operations & Development
Joel D. BeckerChief Executive Officer, President & Director
Amy TreadwellVice President of Human Resources
Katie KellerVice President of Marketing
Leah AkinGeneral Counsel & Corporate Secretary
Rebecca L. KuhnAdvisor